Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 affordable biotech stocks to buy right now.
On July 7, Praxis Precision Medicines Inc. (NASDAQ:PRAX) and Remagine Labs disclosed a research partnership and license agreement to design an iontophoretic transdermal patch for the delivery of ulixacaltamide
Ulixacaltamide is a strongly targeted T-type calcium channel inhibitor of Praxis in the essential tremor development. create jobs 51/ Both companies will use Remagine’s platform, developed for precise, multi-day sustained skin-based dosing, for ulixacaltamide, supporting Praxis’s oral program. On June 29, Praxis Precision Medicines disclosed that the FDA allowed a three-month extension to the NDA review for relutrigine, a treatment for epileptic and SCN2A & SCN8A developmental encephalopathy. The new PDUFA target date has been extended from September 27 to December 27.
The extension came after the company had submitted further sensitivity analyses around the current clinical results, which were labeled as a “major amendment” by the FDA. No new clinical trials were requested, and the company was not asked to address any safety or manufacturing issues. Praxis is optimistic about the data on relutrigine and has prepared for the eventual launch of the product.